23/10/2014

NICE National Institute for Health and Care Excellence

1st Floor
10 Spring Gardens
London
SW1A 2BU

Tel: 0845 003 7780
Fax: 0845 003 7784

www.nice.org.uk

Dear [redacted]

Further to the clarification questions sent on Monday, please note we have one further clarification question relating to the clinical effectiveness section:

A19. On page 63 it is mentioned that "*baseline characteristics appear similar in all treatment arms"* however, Table 8 on page 56 shows that a higher percentage of HCV patients in the everolimus arm of the trial and a higher percentage of hepatocellular carcinoma cases in the tacrolimus arm. Please explain these imbalances.

We would appreciate a response by 5pm on 03 November 2014.

Kind regards